Monoclonal antibody treatments for multiple sclerosis.

Current Neurology and Neuroscience Reports
John W RoseNoel Carlson

Abstract

Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory treatments, MAbs are an important new treatment option. Currently, MAbs are approved by the US Food and Drug Administration for treatment of many conditions, including autoimmune diseases. Four MAbs that have been investigated as potential treatments for MS are reviewed in this article. Of these MAbs, natalizumab is approved for treatment of MS. The other three MAbs (alemtuzumab, rituximab, and daclizumab) are all promising therapies in development for treatment of MS. Adverse effects are relatively mild for these MAbs; however, care in administration and management of these agents is emphasized. Overall, these MAb therapies have great promise in the treatment of MS.

References

Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C QueenT A Waldmann
Jul 1, 1996·The Journal of Thoracic and Cardiovascular Surgery·M D PlunkettJ E Lowe
Jul 1, 1996·Multiple Sclerosis : Clinical and Laboratory Research·T MoreauA Compston
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·R B NussenblattS M Whitcup
Oct 29, 2000·Annals of the Rheumatic Diseases·J C Morris, T A Waldmann
Nov 10, 2001·Hematology·Thomas A. WaldmannBarry S. Coller
Jan 3, 2003·The New England Journal of Medicine·David H MillerUNKNOWN International Natalizumab Multiple Sclerosis Trial Group
Jan 30, 2004·Annual Review of Medicine·William RastetterChristine A White
May 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Bibiana BielekovaRoland Martin
Oct 23, 2004·Annals of Neurology·John W RoseNoel G Carlson
Apr 9, 2005·Current Treatment Options in Neurology·Dean M Wingerchuk, Brian G Weinshenker
Mar 3, 2006·The New England Journal of Medicine·Chris H PolmanUNKNOWN AFFIRM Investigators
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Mar 3, 2006·The New England Journal of Medicine·Tarek A YousryDavid B Clifford
Apr 6, 2006·Proceedings of the National Academy of Sciences of the United States of America·Bibiana BielekovaRoland Martin
Aug 15, 2006·Journal of Neuroimmunology·Anne H CrossJeri-Anne Lyons
Apr 25, 2007·Neurology·D H MillerUNKNOWN AFFIRM Investigators
Jul 31, 2007·The New England Journal of Medicine·UNKNOWN International Multiple Sclerosis Genetics ConsortiumStephen L Hauser
Aug 19, 2007·Annals of Neurology·Richard A RudickUNKNOWN AFFIRM and SENTINEL Investigators
Sep 1, 2007·Neurology·P A CalabresiUNKNOWN AFFIRM and SENTINEL Investigators
Sep 8, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Kate Traynor
Oct 31, 2007·Annals of Neurology·Bernhard Hemmer, Hans-Peter Hartung
Feb 8, 2008·The New England Journal of Medicine·John T MullenMichael B Atkins
Feb 15, 2008·The New England Journal of Medicine·Henry F McFarland
Feb 15, 2008·The New England Journal of Medicine·Stephen L HauserUNKNOWN HERMES Trial Group

❮ Previous
Next ❯

Citations

Nov 15, 2008·Nature Reviews. Immunology·Rachel R Caspi
May 9, 2014·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Daniele de Paula FariaErik de Vries
Nov 27, 2009·Expert Opinion on Investigational Drugs·Luis Rodrigo
Jun 19, 2010·Progress in Neurobiology·Eilhard MixUwe K Zettl
Mar 31, 2009·La Presse médicale·Luc Mouthon
Sep 4, 2015·Nanoscale·Gregg A Duncan, Michael A Bevan
Mar 17, 2010·Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society·Marie NameyCynthia Bishop
Jul 1, 2011·International Journal of MS Care·John F Foley, Anne M Dunne
Oct 9, 2012·Expert Review of Neurotherapeutics·Mohsen Khoshnam, Mark S Freedman
Aug 20, 2014·Frontiers in Neuroscience·Sung-Joo LimLori L Holt
Jul 18, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Joana DuarteLuis Graca

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.